Press Releases

RANCHO CUCAMONGA, Calif. , March 05, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its fourth quarter of 2017 ended December 31, 2017 , after the market closes on Monday, March 12, 2018 , and will hold a conference call to

RANCHO CUCAMONGA, Calif., Dec. 19, 2017 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc., (NASDAQ: AMPH) announced that today the U.S. Food and Drug Administration ("FDA") granted approval of its abbreviated new drug application ("ANDA") for Sodium Nitroprusside Injection 25mg/mL, 2mL single

RANCHO CUCAMONGA, Calif., Nov. 29, 2017 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc., (NASDAQ:AMPH) announced that today the U.S. Food and Drug Administration ("FDA") granted approval of two abbreviated new drug applications (ANDAs) for Medroxyprogesterone Acetate Injectable Suspension, USP,

RANCHO CUCAMONGA, Calif., Nov. 20, 2017 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Jason Shandell, President and Bill Peters, CFO will be presenting at the 29th Annual Piper Jaffray Healthcare Conference on Wednesday, November 29, 2017 at 10:30 a.m.

Reports Net Revenues of $57.9 Million for the Three Months Ended September 30, 2017

RANCHO CUCAMONGA, Calif., Oct. 31, 2017 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its third quarter of 2017, ended September 30, 2017, after the market closes on Wednesday, November 8, 2017, and will hold a conference call

RANCHO CUCAMONGA, Calif., Sept. 25, 2017 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc., (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") granted approval of its abbreviated new drug application (ANDA) for Neostigmine Methylsulfate Injection, USP, 1mg/mL, 10mL, and

RANCHO CUCAMONGA, Calif., Sept. 20, 2017 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that on September 19, 2017, the U.S. Food and Drug Administration ("FDA") granted approval of the company's abbreviated new drug application ("ANDA") for Sodium Bicarbonate injection

RANCHO CUCAMONGA, Calif., Aug. 30, 2017 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Jason Shandell, President will be presenting at the 2017 Wells Fargo Securities Healthcare Conference on Wednesday, September 6, 2017 at 1:50 p.m.

Reports Net Revenues of $65.2 Million for the Three Months Ended June 30, 2017